Quarterly report pursuant to Section 13 or 15(d)

Non-Controlling Interests - Summary Of Non-controlling Interests in Consolidated Entities (Detail)

v3.10.0.1
Non-Controlling Interests - Summary Of Non-controlling Interests in Consolidated Entities (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Noncontrolling Interest [Line Items]          
NCI equity share     $ 90,118   $ 100,889
Net gain/(loss) attributable to non-controlling interests $ (11,949) $ (9,191) (43,254) $ (17,355) (32,960)
Non-controlling interests in consolidated entities 46,864   46,864   67,929
Aevitas [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     (456)   (126)
Net gain/(loss) attributable to non-controlling interests     (397)   (168)
Non-controlling interests in consolidated entities $ (853)   $ (853)   $ (294)
Non-controlling ownership 37.00%   37.00%   35.40%
Avenue [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share [1]     $ 13,043   $ 17,454
Net gain/(loss) attributable to non-controlling interests [1]     (11,232)   (4,646)
Non-controlling interests in consolidated entities [1] $ 1,811   $ 1,811   $ 12,808
Non-controlling ownership [1] 64.80%   64.80%   66.10%
Caelum [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     $ (2,387)   $ (815)
Net gain/(loss) attributable to non-controlling interests     (1,841)   (1,262)
Non-controlling interests in consolidated entities $ (4,228)   $ (4,228)   $ (2,077)
Non-controlling ownership 37.00%   37.00%   34.70%
Cellvation [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     $ (447)   $ (259)
Net gain/(loss) attributable to non-controlling interests     (137)   (96)
Non-controlling interests in consolidated entities $ (584)   $ (584)   $ (355)
Non-controlling ownership 21.70%   21.70%   21.50%
Checkpoint Therapeutics, Inc [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share [2]     $ 30,837   $ 21,635
Net gain/(loss) attributable to non-controlling interests [2]     (15,601)   (12,314)
Non-controlling interests in consolidated entities [2] $ 15,236   $ 15,236   $ 9,321
Non-controlling ownership [2] 69.20%   69.20%   62.00%
Coronado SO [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     $ (290)   $ (236)
Net gain/(loss) attributable to non-controlling interests     0   (54)
Non-controlling interests in consolidated entities $ (290)   $ (290)   $ (290)
Non-controlling ownership 13.00%   13.00%   13.00%
Cyprium [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     $ (197)   $ (143)
Net gain/(loss) attributable to non-controlling interests     (68)   (15)
Non-controlling interests in consolidated entities $ (265)   $ (265)   $ (158)
Non-controlling ownership 10.80%   10.80%   11.10%
Helocyte [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     $ (3,285)   $ (1,907)
Net gain/(loss) attributable to non-controlling interests     (464)   (1,193)
Non-controlling interests in consolidated entities $ (3,749)   $ (3,749)   $ (3,100)
Non-controlling ownership 19.80%   19.80%   20.00%
JMC [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     $ (456)   $ (469)
Net gain/(loss) attributable to non-controlling interests     197   7
Non-controlling interests in consolidated entities $ (259)   $ (259)   $ (462)
Non-controlling ownership 6.30%   6.30%   6.30%
Mustang Therapeutics, Inc [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share [1]     $ 38,147   $ 48,740
Net gain/(loss) attributable to non-controlling interests [1]     (11,174)   (11,911)
Non-controlling interests in consolidated entities [1] $ 26,973   $ 26,973   $ 36,829
Non-controlling ownership [1] 60.00%   60.00%   61.60%
National Holdings [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     $ 15,805   $ 17,021
Net gain/(loss) attributable to non-controlling interests     (2,345)   (1,216)
Non-controlling interests in consolidated entities $ 13,460   $ 13,460   $ 15,805
Non-controlling ownership 43.70%   43.70%   43.40%
Tamid [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     $ (196)   $ (6)
Net gain/(loss) attributable to non-controlling interests     (192)   (92)
Non-controlling interests in consolidated entities $ (388)   $ (388)   $ (98)
Non-controlling ownership 24.00%   24.00%   24.00%
[1] Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights.
[2] Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.